BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 11443157)

  • 1. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy.
    Kuperman H; Damiani D; Chrousos GP; Dichtchekenian V; Manna TD; Filho VO; Setian N
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2993-6. PubMed ID: 11443157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of the rat hypothalamic-pituitary-adrenal axis after discontinuation of prolonged treatment with the synthetic glucocorticoid agonist dexamethasone.
    Calogero AE; Kamilaris TC; Johnson EO; Tartaglia ME; Chrousos G
    Endocrinology; 1990 Oct; 127(4):1574-9. PubMed ID: 2169393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal axis function after high-dose steroid therapy for childhood acute lymphoblastic leukemia.
    Einaudi S; Bertorello N; Masera N; Farinasso L; Barisone E; Rizzari C; Corrias A; Villa A; Riva F; Saracco P; Pastore G
    Pediatr Blood Cancer; 2008 Mar; 50(3):537-41. PubMed ID: 17828747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early adrenocortical recovery after glucocorticoid therapy in children with leukemia.
    Cunha Cde F; Silva IN; Finch FL
    J Clin Endocrinol Metab; 2004 Jun; 89(6):2797-802. PubMed ID: 15181060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
    Rensen N; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008727. PubMed ID: 29106702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of recovery of adrenal function in children treated for leukemia.
    Felner EI; Thompson MT; Ratliff AF; White PC; Dickson BA
    J Pediatr; 2000 Jul; 137(1):21-4. PubMed ID: 10891816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
    Gordijn MS; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
    Cochrane Database Syst Rev; 2012 May; (5):CD008727. PubMed ID: 22592733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
    Gordijn MS; Rensen N; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
    Cochrane Database Syst Rev; 2015 Aug; (8):CD008727. PubMed ID: 26282194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of hypothalamic-pituitary-adrenal axis recovery after corticotherapy by using basal cortisol secretion].
    Silva IN; Cunha CF; Finch FL; Colosimo EA
    Arq Bras Endocrinol Metabol; 2006 Feb; 50(1):118-24. PubMed ID: 16628284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary-adrenal suppression and recovery in preterm very low birth weight infants after dexamethasone treatment for bronchopulmonary dysplasia.
    Ng PC; Wong GW; Lam CW; Lee CH; Fok TF; Wong MY; Wong W; Chan DC
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2429-32. PubMed ID: 9253312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hypothalamic-pituitary-adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone.
    Reincke M; Allolio B; Würth G; Winkelmann W
    J Clin Endocrinol Metab; 1993 Jul; 77(1):151-6. PubMed ID: 8392081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pituitary corticotroph is not the rate limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing syndrome.
    Gomez MT; Magiakou MA; Mastorakos G; Chrousos GP
    J Clin Endocrinol Metab; 1993 Jul; 77(1):173-7. PubMed ID: 8392083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired adrenal function after glucocorticoid therapy in children with acute lymphoblastic leukemia.
    Petersen KB; Müller J; Rasmussen M; Schmiegelow K
    Med Pediatr Oncol; 2003 Aug; 41(2):110-4. PubMed ID: 12825213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothalamic-pituitary-adrenal axis following glucocorticoid prophylaxis against acute mountain sickness.
    Basu M; Sawhney RC; Kumar S; Pal K; Prasad R; Selvamurthy W
    Horm Metab Res; 2002 Jun; 34(6):318-24. PubMed ID: 12173072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy.
    Schürmeyer TH; Tsokos GC; Avgerinos PC; Balow JE; D'Agata R; Loriaux DL; Chrousos GP
    J Clin Endocrinol Metab; 1985 Jul; 61(1):22-7. PubMed ID: 2987294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test.
    Rix M; Birkebaek NH; Rosthøj S; Clausen N
    J Pediatr; 2005 Nov; 147(5):645-50. PubMed ID: 16291357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease.
    Avgerinos PC; Nieman LK; Oldfield EH; Loughlin T; Barnes KM; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1989 May; 68(5):912-6. PubMed ID: 2541160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRH test prior to discontinuation of long-term low-dose glucocorticoid therapy.
    Gellner R; Stange M; Schiemann U; Domschke W; Hengst K
    Exp Clin Endocrinol Diabetes; 1999; 107(8):561-7. PubMed ID: 10612488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reference ranges and factors affecting the human corticotropin-releasing hormone test in preterm, very low birth weight infants.
    Ng PC; Lam CW; Lee CH; Ma KC; Fok TF; Chan IH; Wong E
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4621-8. PubMed ID: 12364445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
    Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.